Literatura académica sobre el tema "Y220C"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Y220C".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Y220C"
Gener-Ricos, Georgina, Jan Philipp Bewersdorf, Sanam Loghavi, Aaron D. Goldberg, Christopher Famulare, Ghayas C. Issa, Gautam Borthakur et al. "TP53 Y220C Mutations in Patients with Myeloid Malignancies". Blood 142, Supplement 1 (28 de noviembre de 2023): 1477. http://dx.doi.org/10.1182/blood-2023-189343.
Texto completoCarter, Bing Z., Po Yee Mak, Baozhen Ke, Yuki Nishida, Steffen Boettcher, Andrea Bedoy, Lauren B. Ostermann et al. "Selective Targeting of TP53-Y220C Mutant AML By PC14586 Results in TP53 Wild-Type Conformation and Synergistical Apoptosis Induction By Concomitant Inhibition of Xpo-1, MDM2, or Bcl-2". Blood 142, Supplement 1 (28 de noviembre de 2023): 2261. http://dx.doi.org/10.1182/blood-2023-181186.
Texto completoPuzio-Kuter, Anna M., Chris Mulligan, Brandon Russo, Amy Wiebesiek, Lizhong Xu, Hong Yang, Binh Vu y Melissa Dumble. "Abstract 1295: Small molecule reactivators of Y220C mutant p53 modulate tumor infiltrating leukocytes and synergize with immune checkpoint inhibitors". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 1295. http://dx.doi.org/10.1158/1538-7445.am2022-1295.
Texto completoZheng, Qian, Peng Wang, Chen Liang, Yao Li, Xin Sun, Amin Li, Wei Zhang, Wei Long y Yanping Wang. "Abstract 5940: JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 5940. http://dx.doi.org/10.1158/1538-7445.am2024-5940.
Texto completoLiu, Meng, Kaijun Geng, Biao Lu, Yuanfeng Xia y Fanglong Yang. "Abstract 7275: GS-P-328, a brain-penetrant small molecule p53 Y220C reactivator for tumors harboring p53 Y220C mutation". Cancer Research 84, n.º 6_Supplement (22 de marzo de 2024): 7275. http://dx.doi.org/10.1158/1538-7445.am2024-7275.
Texto completoValenzuela-Chavira, Ignacio, Salvador Meneses-Sagrero, Aldo A. Arvizu-Flores, Javier Hernández-Paredes, Luisa Rascón-Valenzuela, Carlos A. Velázquez-Contreras y Ramón E. Robles-Zepeda. "Molecular Docking of the Cardenolides of Asclepias subulata in the Human p53 Protein Reveals an Interaction in the Cleft of the Y220C Mutant". Current Chemical Biology 15, n.º 3 (septiembre de 2021): 222–33. http://dx.doi.org/10.2174/2212796815666211026112056.
Texto completoBauer, Matthias R., Rhiannon N. Jones, Raysa K. Tareque, Bradley Springett, Felix A. Dingler, Lorena Verduci, Ketan J. Patel, Alan R. Fersht, Andreas C. Joerger y John Spencer. "A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C". Future Medicinal Chemistry 11, n.º 19 (octubre de 2019): 2491–504. http://dx.doi.org/10.4155/fmc-2019-0181.
Texto completoBaud, Matthias G. J., Matthias R. Bauer, Lorena Verduci, Felix A. Dingler, Ketan J. Patel, Deeptee Horil Roy, Andreas C. Joerger y Alan R. Fersht. "Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines". European Journal of Medicinal Chemistry 152 (mayo de 2018): 101–14. http://dx.doi.org/10.1016/j.ejmech.2018.04.035.
Texto completoSchram, Alison M., Geoffrey I. Shapiro, Melissa L. Johnson, Anthony W. Tolcher, John A. Thompson, Anthony B. El-Khoueiry, Andrae L. Vandross et al. "Abstract LB_A25: Updated Phase 1 results from the PYNNACLE Phase 1/2 study of PC14586, a selective p53 reactivator, in patients with advanced solid tumors harboring a TP53 Y220C mutation". Molecular Cancer Therapeutics 22, n.º 12_Supplement (1 de diciembre de 2023): LB_A25. http://dx.doi.org/10.1158/1535-7163.targ-23-lb_a25.
Texto completoLane, David P. y Chandra S. Verma. "Covalent Rescue of Mutant p53". Cancer Discovery 13, n.º 1 (9 de enero de 2023): 14–16. http://dx.doi.org/10.1158/2159-8290.cd-22-1212.
Texto completoTesis sobre el tema "Y220C"
Jones, Rhiannon N. "Towards the design and synthesis of a p53 mutant Y220C rescue drug". Thesis, University of Sussex, 2018. http://sro.sussex.ac.uk/id/eprint/74884/.
Texto completoEldawra, Eliana. "Effets tératogénique et oncogénique de la mutation Trp53 Y217C". Electronic Thesis or Diss., Sorbonne université, 2024. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2024SORUS072.pdf.
Texto completoThe TP53 gene is the most frequently mutated gene in human cancers. It is responsible for the production of the transcription factor p53, also known as the 'guardian of the genome', with diverse cellular functions and complex regulations, widely recognized today for its role in tumor suppression. My thesis focused on the study and characterization of the p53Y217C mutation in mice (corresponding to p53Y220C in humans). Most TP53 mutations affect the DNA-binding domain of the protein and are generally found at seven mutational hotspots. Of these, the Y220C mutation is of particular interest, being present in 100,000 new cases of cancer per year and in 15 cancer-prone Li-Fraumeni families. To study this mutation in vivo, we developed a mouse model expressing a p53 protein with the Y217C mutation, equivalent to Y220C in humans. Phenotypic characterization of this mouse revealed that the mutation not only deactivates the function of the protein, but also appears to confer new teratogenic and oncogenic functions
Libros sobre el tema "Y220C"
Books, Bchimak. Libro de Contabilidad Ingresos y Gastos: Libro de Cuentas Simple y Fácil de Usar para Autónomos y Cuentas Profesionales, Cuaderno de Ingresos y Gastos Simple. Y220. Independently Published, 2021.
Buscar texto completoActas de conferencias sobre el tema "Y220C"
Dumble, Melissa, Lizhong Xu, Romyr Dominique, Binbin Liu, Hong Yang, Mary-Kate McBrayer, Dafydd Thomas et al. "Abstract LB006: PC14586: The first orally bioavailable small molecule reactivator of Y220C mutant p53 in clinical development". En Proceedings: AACR Annual Meeting 2021; April 10-15, 2021 and May 17-21, 2021; Philadelphia, PA. American Association for Cancer Research, 2021. http://dx.doi.org/10.1158/1538-7445.am2021-lb006.
Texto completoArowosafe, Toyin, Lucky Ishomo, Anthony Ogbebor, Esigie Benson y Rita Aigbefo. "Thru Tubing Gaslift Installation Techniques in Dual Completion for Production Optimization and Improved Recovery in Brown Field Reservoirs". En SPE Nigeria Annual International Conference and Exhibition. SPE, 2023. http://dx.doi.org/10.2118/217476-ms.
Texto completo